Report Scope:
This report will provide a detailed look at the pulmonary drug delivery systems market, highlighting major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis. The report includes an industry-wide assessment of the novel products, launches, recent approvals, R&D pipeline and blockbuster drugs.
In the report, the regulatory scenario of pulmonary drug delivery systems is discussed for each device type. This will include products approved by regulatory authorities in recent years. Products under development or in different stages of clinical trials are also analyzed.
The report includes profiles of major companies in the market for pulmonary drug delivery systems, with overviews of their key product offerings and financials.
Report Includes:
44 tables
A brief overview and up-to-date analysis of the global markets for pulmonary drug delivery systems
Analyses of the global market trends, with historic market revenue data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
Estimation of the actual market size and revenue forecast for pulmonary drug delivery systems in USD value terms, and their corresponding market share analysis by type of drug delivery systems, application/disease area and region
Highlights of the major pulmonary diseases with detailed epidemiology for major disease areas such as asthma, COPD and cystic fibrosis; also, an industry-wide assessment of the key developments, novel products, recent approvals, R&D activities, pipeline products and blockbuster drugs
In-depth information (facts and figures) concerning market drivers, opportunities and challenges, and other macroeconomic forces affecting the global pulmonary drug delivery systems market
Holistic review of the international regulatory landscape for pulmonary drug delivery systems with emphasis on recently approved products as well as products under development or in different stages of clinical trials
Updated information on key mergers and acquisition deals, agreements, collaborations and other impactful strategies adopted by key players in the global pulmonary drug delivery systems market
Assessment of the recent patents published and granted on pulmonary drug delivery systems and related technologies
Identification of the major stakeholders and analysis of the competitive landscape based on recent developments and segmental revenues
Descriptive company profiles of the market leading players, including Abbott, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline PLC, Lupin and Pfizer Inc.
Companies Mentioned
3M
ABBOTT LABORATORIES
ASTRAZENECA
BOEHRINGER INGELHEIM GMBH
CIPLA
DR. REDDY’S LABORATORIES LTD.
GLAXOSMITHKLINE PLC
LUPIN
MERCK KGAA
MYLAN N.V.
NOVARTIS AG
OMRON CORP.
PFIZER INC.
PHILIPS RESPIRONICS
PULMATRIX INC.
TEVA PHARMACEUTICALS INDUSTRIES LTD.
- Chapter 1 Introduction
- 1.1 Study Goals and Objectives
- 1.2 Reasons for Doing This Study
- 1.3 What's New in This Update?
- 1.4 Scope of Report
- 1.5 Information Sources
- 1.5.1 Secondary Research
- 1.5.2 Primary Research
- 1.6 Methodology
- 1.7 Geographic Breakdown
- 1.8 Analyst's Credentials
- 1.9 BCC Custom Research
- 1.10 Related BCC Research Reports
- Chapter 2 Summary and Highlights
- Chapter 3 Market Dynamics and Technology Background
- 3.1 Market Definition and Overview
- 3.1.1 Mechanism of Action
- 3.1.2 Advantages
- 3.1.3 Limitations/Challenges
- 3.2 Pulmonary Conditions and Therapies
- 3.2.1 Introduction to the Respiratory System
- 3.3 Market Drivers and Trends
- 3.3.1 Improved Patient Compliance and Ease of Use
- 3.3.2 Cost Pressures on Countries
- 3.3.3 Rising Incidence of Asthma
- 3.3.4 Causes
- 3.3.5 Reducing the Burden of Asthma
- 3.4 Market Restraints
- 3.4.1 Competition from Generics on the Rise
- 3.5 Market Opportunities
- 3.5.1 Introduction of Smart Nebulizers
- 3.6 Regulation and Legislation
- 3.6.1 U.S.
- Chapter 4 Market Breakdown by Pulmonary Drug Delivery Systems
- 4.1 Overview of Inhalation Techniques
- 4.2 Dry Powder Inhalers (DPIs)
- 4.2.1 Overview
- 4.2.2 Marketed Products
- 4.3 Metered Dose Inhalers (MDIs)
- 4.3.1 Overview
- 4.3.2 Marketed Products
- 4.4 Nebulizers
- 4.4.1 Overview
- 4.4.2 Marketed Products Overview by Manufacturer
- Chapter 5 COVID-19 Impact
- 5.1 Overview
- 5.2 COVID-19 Crisis
- 5.3 Impact on Market for Pulmonary Drug Delivery Systems
- 5.4 Current Outlook
- Chapter 6 Pulmonary Drug Delivery Systems in Use
- 6.1 Therapeutic Agents Administered via Inhalation
- 6.1.1 Steroids
- 6.1.2 Bronchodilators
- Chapter 7 Market Breakdown by Disease Area
- 7.1 Introduction
- 7.2 Asthma
- 7.2.1 Asthma Attacks
- 7.2.2 Asthma and Obesity
- 7.2.3 Mortality
- 7.2.4 Disease Classification
- 7.2.5 Diagnosis
- 7.2.6 Treatment and Therapies
- 7.2.7 Market Size and Forecasts
- 7.3 Chronic Obstructive Pulmonary Disease (COPD)
- 7.3.1 Diagnosis
- 7.3.2 Treatment and Therapies
- 7.3.3 Market Size and Forecasts
- 7.4 Other Diseases
- 7.4.1 Market Size and Forecasts
- Chapter 8 Market Breakdown by Region
- 8.1 North America
- 8.1.1 U.S.
- 8.1.2 Canada
- 8.1.3 Mexico
- 8.2 Europe
- 8.2.1 Germany
- 8.2.2 U.K.
- 8.2.3 France
- 8.2.4 Italy
- 8.2.5 Spain
- 8.2.6 Rest of Europe
- 8.3 Asia-Pacific
- 8.3.1 China
- 8.3.2 Japan
- 8.3.3 India
- 8.3.4 South Korea
- 8.3.5 Rest of Asia-Pacific
- 8.4 Rest of the World
- 8.5 South America
- Chapter 9 Patent Analysis
- 9.1 Overview
- Chapter 10 Company Profiles
- 3M
- ABBOTT LABORATORIES
- ASTRAZENECA
- BOEHRINGER INGELHEIM GMBH
- CIPLA
- DR. REDDY'S LABORATORIES LTD.
- GLAXOSMITHKLINE PLC
- PHILIPS RESPIRONICS
- LUPIN
- MYLAN N.V.
- MERCK KGAA
- NOVARTIS AG
- OMRON CORP.
- PFIZER INC.
- PULMATRIX INC.
- TEVA PHARMACEUTICALS INDUSTRIES LTD.
- Chapter 11 Appendix: Abbreviations
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook